Macrophage inflammatory protein-la (MIP-la) has been assessed for its potential in vivo to protect hematopoietic progenitor cells from the cytotoxic effects of a cycle-specific drug-in this case hydroxyurea (HU). Two doses of HU, 7 hours apart, were administered to mice to induce spleen colony-forming unit (CFU-S) cycling and then to kill them during DNA-synthesis. MIP-la, in a variety of dose and time combinations, was injected before the second dose of HU in an attempt to prevent recruitment or maintain CFU-S quies-
the effects of cytosine arabinoside, a DNA-S phase specific cytotoxic agent6 and that normal, nonproliferating CFU-S could be prevented from entering DNA synthesis, and thus be protected from repeated treatments with hydroxyurea (HU)? However, in the latter experiments, the efficiency of protection was poor, probably because of the use of crude material that had to be used in large quantities, thus restricting the full assessment of its potential.
Recently, the inhibitor has been characterized' and found to be identical to murine macrophage inflammatory protein-la (MIP-la), an 8-Kd molecular weight glycoprotein. Various studies using this molecule, and other members of the MIP family are now showing a wider range of hematopoietic effects and in vitro colony formation studies using them in combination with growth factors led Broxmeyer et al* to the conclusion that MIP-la, MIP-1P, and MIP-2 "may have direct colony enhancing activity for mature progenitors while MIP-la may have direct suppressing activity for more immature progenitors." In addition, Bodine et aI9 recently demonstrated a 60% inhibition of interleukin-3 (IL-3) and IL-6 enhanced CFU-S numbers in a suspension culture by MIP-la, the molecule shown to have the greatest inhibitory activity of the early cells.' These findings thus corroborate the early promise of the unpurified marrow extracts. The production of MIP-la using recombinant DNA technology and its purification is now permitting a fuller survey of its potential for clinical use.10 In this report we show that purified, recombinant murine MIP-la can effectively block the recruitment of CFU-S into cence, and thus protect them from the second dose of HU. Without MIP-la, recovery of the CFU-S population was complete in 7 days. In a dose-dependent manner, MIP-la either reduced the initial kill and accelerated recovery, or completely protected the CFU-S population. We conclude that MIP-la does protect multipotent progenitor cells in vivo and that these observations provide a base from which to build practical clinical applications.
o 1992 by The American Society of Hematology.
cycle, thus protecting those cells from the cytotoxic effect of further treatments with HU.
MATERIALS AND METHODS
Mice. Female BDFl (C52316 X DBA2) mice aged 9 to 10 weeks were used throughout. The mice weighed between 22 and 27 g.
Recombinant MIP-lawas made from a synthetic gene expressed in yeast and kindly supplied by British Biotechnology Ltd. Its specifications and bioactivity are fully described elsewhere.* In brief, it is a purified protein equivalent to the murine form of MIP-la and it contains less than 2 U endotoxin (200 pg) per milligram of protein. It readily aggregates or polymerizes and, as used, is best described as multimeric.
y-rays; dose rate 0.95 Gy/h) mice as previously described." The irradiated recipient mice (20 per group) were injected intravenously with 0.2 mL of a femoral bone marrow suspension and killed 8 days (10 mice), and 11 days (10 mice) later for spleen colony counting.
Pairs of normal mice were treated over 7 hours with MIP-la and/or HU according to the schedule shown in Table 1 . MIP-la was injected intravenously and HU intraperitoneally, in volumes of 0.2 mL medium. At various times from 3 to 7 days after the first HU injection, femoral marrow was harvested and suspended in Hanks' balanced salt solution. The cellular concentrations of the suspensions were adjusted so that 0.01 to 0.002 of a femur, depending on the time after treatment, was injected into the irradiated CFU-S assay recipients with the aim of generating 10 to 15 colonies per spleen after 8 and 11 days growth. Table 1 , HU (900 mg/kg) was injected at time 0 followed 3 and 6 hours later by MIP-la in various (Fig 1) . Three days after two doses of hydroxyurea (HU) (group 2 mice- Table 1 ) the femur contained only 2600 CFU-S and recovery to about 5000 per femur was complete in 7 days (Fig 1) . No significant difference was seen between numbers of 8-and 11-day colonies during this recovery period.
RESULTS

As shown in
In group 4 mice, receiving 10 and 5 pg MIP-la at 3 and 6 hours, respectively (Fig lA) , the femur contained about 40% more CFW-S 3 days after the start of treatment than did those treated with HU alone. Recovery to normal or supranormal levels was complete in 5 days. Increasing the MIP-la doses to 15 + 5 pg (group 6, Fig 1B) (-) and 11-day (---) CFU-S after HU/MIP-la treatment. The numbers indicating data points refer t o the experimental group number as defined in Table l -o p e n for 8-day colonies and in parentheses for 11-day colonies. The bars on the ordinate axis indicate the untreated control levels (e SE) (group 1 mice) in this series of experiments for 8-and 11-day CFU-S. Data for group 2 animals illustrate the recovery curves for HU treatment alone. The data are the means of three separate experiments in each of which two mice were assayed at each time point illustrated. MIP-la dosages are indicated in the lower part of the graphs, giving first the 3-hour injection dose and second the 6-hour injection dose.
the number of 8 day CFU-S per femur at 3 days being 35% higher than in the HU-treated animal but 11 day CFU-S being at the control level-and an earlier recovery than in group 4. An additional small dose (5 pg) at the earlier time point improved the efficiency of the protection (group 8, Fig 1C) . However, a single dose of MIP-la at the 3-hour time point gave little protection from the second dose of HU (group 3, Fig 1D) .
In all treatment regimens in which recovery or protection was complete, the numbers of CFU-S per femur overshot the control levels. However, in all cases of full recovery the marrow cellularity was not measurably different from normal.
DISCUSSION
HU is a cytotoxic drug that kills cells in DNA synthesis and blocks further entry of non-S-phase cells into DNA synthesis for a period of about 4 hours before releasing a semi-synchronized cohort of cells into the next period of DNA synthesis.12J3 Hodgson et aIl3,l4 used this property to synchronize CFU-S, using two doses of HU to recruit and kill a large proportion of CFU-S in DNA synthesis. They observed full recovery within about 1 week. Figure 2 illustrates, on an arbitrary scale, the changes in CFU-S number after these two doses of HU with or without the intervention of MIP-la treatment. CFU-S are normally proliferating only very slowly so that a single dose of HU at 0 hours kills few of them. However, more developed and rapidly proliferating cells in the tissue are killed, and their loss recruits quiescent CFU-S into proliferation when the HU block is relea~ed.l3,'~ Thus, a second dose of HU in mid-S phase (7 hours) kills a large proportion of proliferating CFU-S (illustrated as level 1, Fig 2) and subsequent recovery is complete in about 7 days (Figs 1 and 2) . As an inhibitor of CFU-S proliferation, MIP-la has been used in an attempt to prolong the HU-induced block, to prevent the semi-synchronous release of CFU-S into S-phase and thus to protect potentially cycling CFU-S against a subsequent dose of the cytotoxic agent. This should reduce the effectiveness of the second HU dose (illustrated as level 2, Fig 2) with subsequent earlier recovery. In a clinical situation this would theoretically allow dose intensification either by use of an increased second dose of HU and/or earlier treatment in a second round of cytotoxic therapy. We chose to study the recovery from day 3 after treatment (levels 1' and 2' , Fig 2) to assess the recovering CFU-S population rather than measure the CFU-S initially surviving the second dose of HU, some of which may not contribute directly to the ultimate recovery of the population.
Early experiments with the crude, fresh bone marrowderived inhibitor indicated that such an approach would be a practical proposition. 6 The present experiments using the recombinant MIP-la have extended those observations and, with the appropriate dosages, it is clear that complete protection of the CFU-S from the cytotoxic effects of HU can be obtained (Fig 1) .
Preliminary experiments with MIP-la indicated that 10 pglmouse is an effective dose in vivo for inhibition of proliferating CFU-S.lo In the present experiments a combination of doses from 0 to 15 kg/mouse has been used. Figure 3 shows the relative initial protection obtained at 3 days after MIP-la treatment (position 2' , Fig 2) relative to the HU treatment alone (1', for group 2 mice, Fig 2) . Escalating doses clearly give increasing protection while dose combinations at the higher levels appear to give enhanced CFU-S numbers. The reason for this latter observation is not known but a similar phenomenon has use only. been noted in long-term bone marrow culture in which inhibitor treatment led to more cellular cultures over at least 3 weeks after treatment.15 In addition, it is interesting that the CFU-S recovery rates in groups 4 ( Fig 1A) and 5 (Fig 1B) appear to have been increased. At this time there is no definitive explanation for the apparently improved CFU-S performance, but these observations suggest that MIP-la may have secondary effects on the self-renewal and/or differentiation rates of the CFU-S. It is also interesting that the cellularity of the recovered marrow is comparable in all groups so that compensatory post-CFU-S proliferation changes might also be expected, probably as an indirect effect of the CFU-S response to MIP-la. Increased proliferation rates of committed progenitors as reported by Broxmeyer et al* may play an important role in such a process. More detailed experimental procedures will be required to explain this phenomenon fully.
Although there is essentially little difference in the 11-and 8-day CFU-S responses in these experiments, 11-day colony survival seems to have a greater dependency on the second dose of MIP-la, whereas the 8-day CFU-S have a more uniform dependency on the two treatments (rank order, Fig 3) . In addition, relatively higher dose combinations were required to give total protection to the 8-day CFU-S. This is probably related to the earlier observations that the more primitive CFU-S are more sensitive to the effects of inhibitor16J7 and that the second dose is administered during the period when the CFU-S would normally be expected to have entered DNA synthesis.
It could be suggested that some of the observed effects may have been caused by contamination of the MIP-la with endotoxin. It is known that bacterial endotoxin can affect the functioning of hematopoietic tissue. A range of studies using endotoxin doses between 8 and 50 pg showed induced proliferation and increased numbers of CFU-S.18-24 However, such an effect from any significant contamination of the MIP-la with endotoxin would render the CFU-S more sensitive to the final HU treatment and delay the recovery process. In fact, contamination of our preparations of MIP-la is such that the mice received less than 3 pg of endotoxin, a dose more than 106-fold less than the lowest used above. Moreover, in one of our previous studies, we found that picogram quantities of endotoxins had no effect on the CFU-S p o p~l a t i o n .~~ Therefore, it is most unlikely that the protection against HU toxicity seen in these present experiments can be explained by endotoxin in the In practical terms, the doses of MIP-la used in these experiments are quite high and a dose of 15 kg125 g mouse might translate to 36 mg/60 kg patient. It is known that MIP-la molecules readily It is possible that this reduces the efficiency of its use in the marrow and that once this problem can be overcome, much lower doses will be practicable.
In conclusion, MIP-la is able to protect the multipotent progenitor CFU-S population from the effects of an S-phase cytotoxic agent. These observations provide a base from which to build its practical clinical applications, as an adjunct to cycle-specific cytotoxic therapy.
MIP-la.
